At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the July 2026 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we encourage you to visit the actual articles in the journals for full details and to increase your understanding. Check the IMF Newsroom monthly for updates like this one.
In the Journals (Key Myeloma Research in July 2026)
"Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy"
Source
Sofie-Katrin Kadel, Lukas Scheller, Alexander M. Leipold, Tobias Krammer, Tamás Raskó, Miriam Alb, Philipp Weis, Maria Leberzammer, Friederike Schmitt, Clara Stetter, Yoko Tamamushi, Alicia Köck, Philipp Köberle, Martin Reich, Thomas Musacchio, Kathrin Doppler, Claudia Sommer, Nadine Cebulla, Rhonda McFleder, Chi Wang Ip, Jens Volkmann, Matthias Kallius, Sebastian E. Serfling, Philipp E. Hartrampf, Andreas K. Buck, Amit Pande, Dennis Löffler, Michael Gernert, Johannes Duell, Max S. Topp, Julia Mersi, Johannes Waldschmidt, Hermann Einsele, Michael Hudecek, Antoine- Emmanuel Saliba, Leo Rasche, K. Martin Kortüm; Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy. Blood Cancer Discov 1 July 2026; 7 (4): 544-557. https://doi.org/10.1158/2643-3230.BCD-25-0278
Overview
This case study investigated the immune mechanisms behind fatal parkinsonism after ciltacabtagene autoleucel (cilta-cel). Longitudinal cerebrospinal fluid and blood analyses identified a two-phase immune process involving CAR T-cell entry into the central nervous system, inflammation, blood-brain barrier disruption, and neuronal injury.
"Global burden of multiple myeloma (1990–2021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomizatio"
Source
Sofie-Katrin Kadel, Lukas Scheller, Alexander M. Leipold, Tobias Krammer, Tamás Raskó, Miriam Alb, Philipp Weis, Maria LQu, R., Zhang, X., Zou, J. et al. Global burden of multiple myeloma (1990–2021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomization. J Egypt Natl Canc Inst 38, 44 (2026). https://doi.org/10.1186/s43046-026-00377-4 July 9, 2026.
Overview
Researchers analyzed global multiple myeloma trends from 1990 to 2021 and projected the disease burden through 2035. In 2021, an estimated 148,755 people developed myeloma, 116,359 died from it, and men and older adults experienced the greatest burden. The analysis also found substantial regional differences and identified a higher body mass index (BMI) as a potentially modifiable risk factor for myeloma.
Although myeloma rates remain highest in high-income regions, the burden is growing most rapidly in middle-income areas, where access to early diagnosis and advanced treatments may be limited. The findings highlight the need to expand diagnostic and treatment resources, prepare healthcare systems for an aging population, and promote healthy weight management. The researchers project that age-standardized rates may decline through 2035, but the total number of people affected could continue to rise as the global population grows and ages.
"Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma"
Source
Erin W. Meermeier, Dara S. Missan, Latha B. Pathangey, Caleb K. Stein, Gabrielle A. Reckard, Susie A. Darvish, Gregory J. Ahmann, Jill Adamski, Rafael Fonseca, Sandra J. Gendler, Michael P. Gustafson, P. Leif Bergsagel; Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma. Cancer Research Communications 1 July 2026; 6 (7): 1592-1604. https://doi.org/10.1158/27679764.CRC-25-0713
Overview
This phase I study tested whether MUC1-specific T cells could be expanded from the blood of heavily pretreated patients and safely used as adoptive immunotherapy for relapsed or refractory multiple myeloma. Treatment was feasible and well tolerated, although no objective responses occurred; one patient who received the highest dose maintained stable disease for two years.
"Transitioning CAR-T Therapy for Multiple Myeloma to the Outpatient Setting: First Clinical Insights with Cilta-cel in Germany"
Source
Scheid, C., Gödel, P., Krone, C., Carpinteiro, E., Hallek, M., Holtick, U. and Richardson, T. (2026), Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta-cel in Germany. HemaSphere, 10: e70417. https://doi.org/10.1002/hem3.70417 July 1, 2026
Overview
This single-center report evaluated whether selected patients could receive cilta-cel through a structured outpatient program in Germany. The model reduced inpatient bed use by more than 90% while maintaining acceptable safety, suggesting that outpatient treatment may be feasible at experienced centers with stringent selection, close monitoring, and rapid admission pathways.
"Impact of Qualitative and Quantitative Immunoparesis on Early Infection Risk in Patients with Newly Diagnosed Multiple Myeloma"
Source
Wang H, Chen J. Impact of Qualitative and Quantitative Immunoparesis on Early Infection Risk in Patients with Newly Diagnosed Multiple Myeloma. Mediterr J Hematol Infect Dis. 2026 Jul 1;18(1):e2026062. doi: 10.4084/MJHID.2026.062.
Overview
This retrospective study examined whether the presence and severity of immunoparesis predict infection within six months of a new multiple myeloma diagnosis. Immunoparesis strongly increased early infection risk, but the study did not identify a clear risk gradient according to the breadth or depth of immunoglobulin suppression.
"Multiple Myeloma: A Tale of Deregulated Transcription Factors"
Source
Gómez-Echarte, N., San José-Enériz, E., Urizar-Compains, E., Rodriguez- Otero, P., Prósper, F. and Agirre, X. (2026), Multiple myeloma: A tale of deregulated transcription factors. HemaSphere, 10: e70411. https://doi.org/10.1002/hem3.70411 July 1, 2026.
Overview
This review explains how deregulated transcription factors contribute to plasma-cell transformation, multiple myeloma progression, treatment resistance, and relapse. It also evaluates their value as prognostic biomarkers and discusses emerging strategies, including RNA-based therapies and targeted protein degradation, that may make these proteins therapeutically actionable.
"Correlation Between SGK1 Expression Level and Multiple Myeloma Progression After Autologous Hematopoietic Stem Cell Transplantation"
Source
Fan, T., Guo, C., Zhang, Y. et al. Correlation Between SGK1 Expression Level and Multiple Myeloma Progression After Autologous Hematopoietic Stem Cell Transplantation. Biochem Genet (2026). https://doi.org/10.1007/s10528-026-11422-1 July 1, 2026
Overview
This study assessed whether serum and glucocorticoid-inducible kinase 1 (SGK1) expression is associated with disease progression after autologous stem cell transplantation. Higher SGK1 expression correlated with poorer treatment response and adverse disease features, supporting further study of SGK1 as a prognostic biomarker.
"Impact of Doublet Post-Transplant Maintenance on Outcomes in Multiple Myeloma: A Propensity Score Matching Analysis"
Source
Huang, I.J., Baek, G.T., Wu, Q.V. et al. Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis. Bone Marrow Transplant (2026). https://doi.org/10.1038/s41409-026-02955-5 July 1, 2026.
Overview
This real-world analysis compared doublet maintenance with single-agent maintenance after autologous stem cell transplantation. After propensity-score matching, doublet maintenance was associated with longer event-free and overall survival, supporting broader evaluation of multi-agent maintenance approaches.
"Expression Profile of CASSIOPEIA Patients Refines Prognostic Value of MRD Negativity in Multiple Myeloma"
Source
Magrangeas, F., Guérin-Charbonnel, C., Bessonneau-Gaborit, V. et al. Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-02601550-7 July 2, 2026.
Overview
This CASSIOPEIA analysis asked whether baseline gene-expression patterns could refine the prognostic meaning of measurable residual disease (MRD) negativity. Transcriptomic profiling identified biologically distinct risk groups and showed that MRD negativity was less predictive in high-risk disease, supporting the combined use of molecular risk and MRD assessment.
"Clinical Outcomes of ASCT in Multiple Myeloma: A Study by the Plasma Cell Dyscrasia Working Party of PBMT"
Source
Raheel Iftikhar, Danyal Ahmed Ghani, Shahzad Sarwar, Natasha Ali, Nida Anwar, Syed Waqas Bokhari, Saima Humayun, Ayesha Iftikhar, Munira Moosajee, Uzma Zaidi, Usman Ahmad, Bushra Ahsan, Maryam Khan, Aisha Jamal, Salman Naseem Adil, Saad Z. Usmani, Muhammad Ayaz Mir, Clinical Outcomes of ASCT in Multiple Myeloma: A Study by the Plasma Cell Dyscrasia Working Party of PBMT, Blood Global Hematology, 2026, 100121, ISSN 3050-5658, https://doi.org/10.1016/j.bglo.2026.100121. July 2,2026.
Overview
This multicenter study described autologous stem cell transplantation outcomes for 269 patients treated across six centers in Pakistan. The findings showed that transplantation can be effective in a resource-constrained setting and identified deeper response before transplant and higher-dose melphalan conditioning as factors associated with better survival.
"Idecabtagene Vicleucel and Endogenous T-Cell Phenotypes Linked to Progression-Free Survival in Relapsed Multiple Myeloma"
Source
Paiva, B., Manrique, I., Thompson, E., Campbell, T.B., Guerrero, C., Martin, N., Anderson, L.D., Jr., Berdeja, J.G., Lonial, S., Raje, N.S., Lin, Y., Moreau, P., San- Miguel, J.F., Munshi, N.C. and Kaiser, S. (2026), Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma. HemaSphere, 10: e70423. https://doi.org/10.1002/hem3.70423 July 2, 2026.
Overview
This KarMMa trial analysis examined how CAR T-cell and naturally occurring T-cell phenotypes relate to progression-free survival after idecabtagene vicleucel. Immune characteristics before collection and after infusion were associated with outcomes, suggesting potential biomarkers of response and resistance.
"Molecular Determinants of Bortezomib Sensitivity and Resistance in Multiple Myeloma"
Source
Jahir Hossain, Debopriya Choudhury, Soham Bhattacharyya, Brahmachari Vedeshachaitanya, Pushkar Malakar, Molecular determinants of Bortezomib sensitivity and resistance in multiple myeloma, Cancer Treatment and Research Communications, Volume 48, 2026, 101303, ISSN 2468-2942, https://doi.org/10.1016/j.ctarc.2026.101303. July 2, 2026.
Overview
This review synthesizes molecular mechanisms that influence sensitivity and resistance to bortezomib, including p53 loss, Ras and mTOR signaling, Wee1 activity, and long noncoding RNAs. Its purpose is to identify biomarkers and combination strategies that may restore sensitivity and produce more durable responses.
"Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss"
Source
Allinovi, M., Malatesta, L., Biagioli, T., Antonioli, E., & Perfetto, F. (2026). Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss. Antibodies, 15(4), 57. https://doi.org/10.3390/antib15040057 July 2, 2026.
Overview
This review explores less-recognized causes of incomplete, transient, or absent response to daratumumab, with particular attention to anti-daratumumab antibodies and urinary drug loss. The authors argue that standardized antibody testing may be useful after treatment interruption or when patients have inadequate responses or infusion reactions.
"Identification and Validation of Aging-Related Genes in Patients with Multiple Myeloma"
Source
Liu H, Song S, Wu Y, Wang Y, Liu Y, Liu Y. Identification and validation of aging-related genes in patients with multiple myeloma. Oncol Lett. 2026 Jul 2;32(3):384. doi: 10.3892/ol.2026.15739.
Overview
This study used bioinformatics and laboratory validation to identify aging-related genes associated with multiple myeloma. Six candidate genes were identified, with TXN showing the strongest diagnostic potential and higher expression in myeloma cells than in normal B-cell lines.
"Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma"
Source
Irene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, Thomas Melchardt, Michael Leisch, Eduard Schulz, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler-Izmir, Theresa Lentner, Johannes Clausen, Veronika Buxhofer-Ausch, Sigrid Machherndl- Spandl, Olga Saini, Dagmar Wipplinger, Holger Rumpold, Nina Worel, Werner Rabitsch, Axel Schulenburg, Hermine Agis, Maria-Theresa Krauth, Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma, Transplantation and Cellular Therapy, 2026, ISSN 2666-6367, https://doi.org/10.1016/j.jtct.2026.06.048. July 2, 2026.
Overview
This multicenter real-world study assessed whether bridging treatment or underlying disease biology more strongly influences outcomes after BCMA-directed CAR T-cell therapy. Extramedullary disease and plasma cell leukemia were the dominant adverse factors, while intensive bridging itself did not independently worsen toxicity or outcomes.
"Light Chain Monoclonal Gammopathy of Undetermined Significance: Diagnosis, Biology, and Clinical Management"
Source
S. Y. Kristinsson, T. E. Long, and S. Thorsteinsdóttir, “Light Chain Monoclonal Gammopathy of Undetermined Significance: Diagnosis, Biology, and Clinical Management,” European Journal of Haematology (2026): 1-9, https://doi.org/10.1111/ejh.70258.
Overview
This review clarifies the diagnosis, biology, and management of light-chain monoclonal gammopathy of undetermined significance (LC-MGUS). It emphasizes updated reference intervals to reduce overdiagnosis and the need to evaluate separately for progression to light-chain myeloma and transformation to AL amyloidosis.
"Prospective, Multicentre Phase II Study to Evaluate the Clinical Benefit of Reduced-Dose Lenalidomide and Dexamethasone Based on Frailty Stratification in Elderly, Unfit Patients with Newly Diagnosed Multiple Myeloma"
Source
Jung S-H, Kim D, Lee J-J, Choi D, Lee WS, Jung J, et al. Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma. Br J Haematol. 2026;00:1-9. https://doi.org/10.1111/bjh.70663 July 3, 2026.
Overview
This phase II study tested frailty-adapted starting doses of lenalidomide and dexamethasone in older, transplant-ineligible patients with newly diagnosed myeloma. The reduced-dose strategy produced high response rates and manageable toxicity, suggesting that frail patients may retain clinical benefit with treatment tailored to fitness.
"Response Profile and Long-Term Outcomes in Cyclin D1-Overexpressing Multiple Myeloma: Insights from the CASSIOPEIA Trial"
Source
Perrot, A., Touzeau, C., Minvielle, S. et al. Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial. Blood Cancer J. 16, 110 (2026). https://doi.org/10.1038/s41408-026-01542-7 July 3, 2026.
Overview
This Letter to the Editor used long-term CASSIOPEIA data to examine response and survival in patients with cyclin D1 overexpression, a marker associated with t(11;14). Although these patients achieved MRD negativity more slowly and less often, their progression-free and overall survival were similar, cautioning against treatment escalation based on MRD results alone.
"Redefining Light-Chain Smoldering Multiple Myeloma: Prevalence and Progression Risk"
Source
Maeng, C.V., Thorsteinsdóttir, S., Óskarsson, J.Þ. et al. Redefining light-chain smoldering multiple myeloma: prevalence and progression risk. Leukemia (2026). https://doi.org/10.1038/s41375-026-03028-8 July 6, 2026.
Overview
This population-based study aimed to establish a clearer definition of light-chain smoldering multiple myeloma and estimate its prevalence and progression risk. Using iStopMM data with external Danish validation, the researchers combined serum free light-chain testing and bone marrow findings to distinguish this precursor condition more consistently.
"Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Induction Prior to Autologous Haematopoietic Stem Cell Transplant/Transplantation in Newly Diagnosed Multiple Myeloma"
Source
Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma. Br J Haematol. 2026;00:1-10. https://doi.org/10.1111/bjh.70642 July 6, 2026.
Overview
This retrospective comparison evaluated KRd versus VRd induction before autologous transplantation in newly diagnosed multiple myeloma. KRd produced deeper responses, higher MRD-negativity rates, and longer progression-free survival, although overall survival did not differ significantly.
"Comparative Efficacy and Safety of G-CSF Alone Versus G-CSF Combined with Different Doses of Cyclophosphamide for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma"
Source
Mesut Göçer, Erdal Kurtoğlu, Comparative Efficacy and Safety of G-CSF Alone Versus G-CSF Combined with Different Doses of Cyclophosphamide for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma, Transfusion and Apheresis Science, 2026, 104490, ISSN 1473-0502, https://doi.org/10.1016/j.transci.2026.104490. July 7, 2026.
Overview
This study compared G-CSF alone with G-CSF plus low- or intermediate-dose cyclophosphamide for stem cell mobilization. Adding cyclophosphamide improved mobilization success and CD34-positive cell yield, with the higher-dose regimen showing the greatest efficacy without a significant increase in measured toxicity.
"Limited Lenalidomide Exposure and Access to Rescue Plerixafor Can Eliminate Haemopoietic Progenitor Cell First Collection Failure in Bortezomib, Lenalidomide and Dexamethasone Treated Transplant Eligible Multiple Myeloma Patients"
Source
Matsamakis, N., Berry, M., Buehler, J. and Zantomio, D. (2026), Limited lenalidomide exposure and access to rescue plerixafor can eliminate haemopoietic progenitor cell first collection failure in bortezomib, lenalidomide and dexamethasone treated transplant eligible multiple myeloma patients. Intern Med J. https://doi.org/10.1111/imj.70468 July 7, 2026.
Overview
This single-center study evaluated strategies to prevent first-attempt stem cell collection failure after VRd induction. Limiting lenalidomide exposure to fewer than six weeks and allowing rescue plerixafor eliminated collection failures without compromising product quality or engraftment.
"Periplocin Targets STAT3 to Suppress MYC Expression and Inhibit Multiple Myeloma Cell Proliferation"
Source
Rong-fang Wei, Jing-xian Chen, Shu-ping Lai, Zi-ang Chen, Yan-ying Zhou, Ya- ping Liao, Yan Chen, Periplocin targets STAT3 to suppress MYC expression and inhibit multiple myeloma cell proliferation, Journal of Integrative Medicine, 2026, ISSN 2095-4964, https://doi.org/10.1016/j.joim.2026.07.002. July 7, 2026.
Overview
This preclinical study investigated whether periplocin can inhibit multiple myeloma and identified its molecular target. In cell and mouse models, periplocin targeted STAT3, reduced MYC expression, promoted apoptosis, and suppressed tumor growth, supporting further development as a potential therapy.
"Targeting Endoplasmic Reticulum Export Disrupts Metabolic Resilience in Multiple Myeloma"
Source
Horzum, U., Oberacher, H., Haun, M. et al. Targeting endoplasmic reticulum export disrupts metabolic resilience in multiple myeloma. Sig Transduct Target Ther 11, 262 (2026). https://doi.org/10.1038/s41392-026-02833-y July 7, 2026.
Overview
This laboratory study tested whether blocking COPII-dependent export from the endoplasmic reticulum could exploit myeloma cells' dependence on protein secretion. Inhibiting this pathway created proteotoxic and metabolic stress that killed secretory myeloma cells and showed activity in two animal models.
"Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma"
Source
Minghao Dang, Luz Yurany Moreno Rueda, Maria Jose Acevedo Calado, Hima Bansal, David Alejandro Berrios Nolasco, Amishi U Vora, Jonathan D Mejia, Mei Huang, Wei Tan, Li Qin, Yunhe Liu, Yang Liu, David E. Mery, Yan Cheng, Fenghuang Zhan, John D. Shaughnessy, Qing Yi, Pei Lin, Mahmoud R. Gaballa, Oren Pasvolsky, Hans C. Lee, Sheeba K. Thomas, Donna M Weber, Krina K. Patel, Melody R Becnel, Jing Christine Ye, Isere Kuiatse, Elisabet E Manasanch, Linghua Wang, Robert Z. Orlowski; Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma. Blood 2026; blood.2025032630. doi: https://doi.org/10.1182/blood.2025032630 July 7, 2026.
Overview
This single-cell study mapped changes in the bone marrow tumor microenvironment across precursor states and active multiple myeloma. Five immune ecotypes were identified, including patterns associated with tumor expansion, poor outcomes, immunotherapy response, and survival, providing a framework for stage- or ecotype-directed treatment research.
"POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management"
Source
A. Dispenzieri, “POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management,” American Journal of Hematology (2026): 1-20, https://doi.org/10.1002/ajh.70438 July 7, 2026.
Overview
This clinical update summarizes current approaches to diagnosing, risk-stratifying, treating, and monitoring POEMS syndrome. Its purpose is to improve recognition of this plasma cell disorder and guide therapy according to disease distribution while emphasizing supportive care and caution with neurotoxic treatments.
"PET/CT Imaging for Therapy Assessment in Multiple Myeloma Including MRD"
Source
Daverio, A. L., Coccarelli, A., Henry, T., Danu, A., Agrigoroaie, L., Trabelsi, K., Kamoun, T., Rovera, G., Morbelli, S., & Deandreis, D. (2026). PET/CT Imaging for Therapy Assessment in Multiple Myeloma Including MRD. Cancers, 18(14), 2184. https://doi.org/10.3390/cancers18142184 July 7, 2026.
Overview
This literature review evaluated PET/CT for measuring treatment response and MRD in symptomatic multiple myeloma. It concludes that PET/CT adds whole-body assessment of metabolically active and extramedullary disease and is most informative when integrated with standardized criteria and bone marrow MRD testing.
"Elranatamab: A Novel B-Cell Maturation T-Cell Engager"
Source
Hossain, S., & Bianchi, G. (2026). Elranatamab: A novel B-cell maturation T-cell engager. Human Vaccines & Immunotherapeutics, 22(1). https://doi.org/10.1080/21645515.2026.2694852 July 7, 2026.
Overview
This review describes elranatamab's mechanism, efficacy, and safety as a BCMA-by-CD3 bispecific antibody for relapsed or refractory multiple myeloma. It also places cytokine release syndrome and neurotoxicity in context and discusses ongoing evaluation in combinations and earlier treatment lines.
"Natural Killer Cells from Patients Relapsing on Daratumumab Therapy Express an Exhausted-Associated Phenotype"
Source
Fladeland Iversen K, Nederby L, Lund T, Andreasen Leth T, Plesner T. Natural killer cells from patients relapsing on daratumumab therapy express an exhausted- associated phenotype. Clin Hematol Int. 2026 Jul 7;8(3):1-9. doi: 10.46989/001c.163405.
Overview
This study compared natural killer cells from newly diagnosed patients with those from patients progressing on daratumumab. Progression was associated with fewer cytotoxic NK cells and a more exhausted, inhibitory phenotype, although further work is needed to determine whether this pattern causes, marks, or results from resistance.
"Signals in Peripheral Blood: Tracking Redox Status and DNA Damage Response During the Progression of Multiple Myeloma"
Source
Malamos, P., Deligianni, E., Koutoulogenis, K., Courraud, J., Liacos, C.-I., Solia, E., Terpos, E., Dimopoulos, M. A., Kastritis, E., & Souliotis, V. L. (2026). Signals in Peripheral Blood: Tracking Redox Status and DNA Damage Response During the Progression of Multiple Myeloma. International Journal of Molecular Sciences, 27(14), 6103. https://doi.org/10.3390/ijms27146103 July 7, 2026.
Overview
This study asked whether systemic changes in oxidative balance and DNA damage response can be detected in blood as patients progress from MGUS to smoldering and active myeloma. Progressive abnormalities were measurable in peripheral blood mononuclear cells, supporting further evaluation as minimally invasive biomarkers for early detection and prognosis.
"Belantamab Mafodotin, a BCMA-Directed Antibody-Drug Conjugate for Multiple Myeloma"
Source
Samuel, M., Flores, M. S., Lowy, J. A., Rogers, M. F., Avigan, Z. M., Rattu, M. A., & Richter, J. (2026). Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma. Future Oncology, 1-12. https://doi.org/10.1080/14796694.2026.2700028 July 8, 2026.
Overview
This review summarizes the pharmacology, clinical evidence, and safety management of belantamab mafodotin, particularly in the DREAMM-7 and DREAMM-8 combinations. It highlights the convenience of an off-the-shelf BCMA-directed therapy while emphasizing ocular toxicity, ophthalmic monitoring, and the need to optimize dose and schedule.
"CD138 Phenotype-Resolved Immunomagnetic Microfluidic Profiling of Circulating Plasma Cells for Multiple Myeloma Triage"
Source
Yahan Gong, Zhenwei Liang, Jing Zhao, Xu Si, Xiaolei Guo, Wenxuan Fu, Chuan Du, Jiadao Wang, Yuan Ma, Rui Zhang, CD138 phenotype-resolved immunomagnetic microfluidic profiling of circulating plasma cells for multiple myeloma triage, Microchemical Journal, 2026, 118994, ISSN 0026-265X, https://doi.org/10.1016/j.microc.2026.118994. July 8, 2026.
Overview
This engineering study developed a microfluidic method to enrich and quantify CD138-associated circulating plasma cells directly from whole blood. A phenotype-resolved score performed well in blinded validation, supporting its potential as an adjunctive rule-in/rule-out triage tool rather than a stand-alone diagnostic test.
"Rapid Peak Cilta-cel Expansion Is Associated with Delayed Neurotoxicity in Multiple Myeloma"
Source
Hitomi Hosoya, Arash Velayati, Danai Dima, Alexandria Jensen, Andrew J. Portuguese, Vanna Hovanky, Lekha Mikkilineni, Lauren C. Peres, Ariel F Grajales-Cruz, Sylvester Homsy, Masooma Shifa Rana, Juancarlos Cancilla, Sunita Patil, Bita Sahaf, Theresa Latchford, Ciara L Freeman, Brian J Scott, Kun Wei Song, Omar Alexis Castaneda-Puglianini, Humza Khan, Saurabh Dahiya, Frederick L. Locke, Crystal L. Mackall, David B Miklos, Rahul Banerjee, Doris K Hansen, Melissa Alsina, Surbhi Sidana; Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma. Blood 2026; blood.2025032844. doi: https://doi.org/10.1182/blood.2025032844 July 8, 2026.
Overview
This multicenter study examined whether CAR T-cell expansion patterns predict efficacy and toxicity after ide-cel or cilta-cel. Rapid, high cilta-cel expansion and elevated peak absolute lymphocyte counts were associated with delayed neurotoxicity, providing practical thresholds that may help identify patients who need closer monitoring.
"AI-Derived Whole-Body MRI Metrics in Multiple Myeloma Patients Reveal Unique Insights into Body Composition and Outcomes"
Source
Nicolas Basty, Martin F. Kaiser, Charlotte Pawlyn, Kevin D Boyd, Katy Smith, Karen Thomas, Nuria Porta, Davide Meo, Robby Emsley, Jessica Winfield, Alina Dragan, Simon Doran, Dow-Mu Koh, Brandon Whitcher, Christina Messiou; AI derived Whole-Body MRI metrics in multiple myeloma patients reveal unique insights into body composition and outcomes. Blood Adv 2026; bloodadvances.2026020852. doi: https://doi.org/10.1182/bloodadvances.2026020852 July 8, 2026
Overview
This study developed an artificial intelligence pipeline to extract body-composition measures from routine whole-body MRI scans. Muscle loss and fat changes during treatment were associated with progression-free survival, supporting MRI-derived body composition as a scalable prognostic biomarker.
"Missed Opportunities to Promote Flourishing in Cancer Care: A Brief Examination of Multiple Myeloma"
Source
Tuckey, N., Wardill, H.R., Symons, X. et al. Missed opportunities to promote flourishing in cancer care: a brief examination of multiple myeloma. Support Care Cancer 34, 746 (2026). https://doi.org/10.1007/s00520-026-10978-3 July 8, 2026.
Overview
This qualitative study explored whether myeloma care adequately supports meaning, connection, and psychological flourishing near the end of life. Patients wanted more open conversations about death, while clinicians often hesitated; the authors propose earlier palliative care and meaning-centered support without abandoning treatment-related hope.
"A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma."
Source
Hans C. Lee, Wouter J. Plattel, Simon J. Harrison, Douglas W. Sborov, Suzanne Lentzsch, Andrew Spencer, Ruben Niesvizky, Suzanne Trudel, Peter Mollee, Ravi Vij, Monique C. Minnema, Leo Rasche, Vijay V. Upreti, Di Zhou, Qing Xia, Mihaela Talpes, Tobias Eggert, Prashant Kapoor, Sikander Ailawadhi; A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma. Blood 2026; 148 (2): 199-212. doi: https://doi.org/10.1182/blood.2025032044 July 9, 2026.
Overview
This phase 1/1b study evaluated the safety, dosing, pharmacokinetics, and preliminary efficacy of the BCMA-directed bispecific antibody pavurutamab in heavily pretreated, triple-class relapsed or refractory multiple myeloma. The recommended phase 2 dose showed an acceptable safety profile and encouraging activity, supporting continued development.
"Prediagnostic opioid use and survival in multiple myeloma: a nationwide register-based study."
Source
Biel-Nielsen Dietz, J., Kristjánsson, R.P., Davídsson, Ó.B. et al. Prediagnostic opioid use and survival in multiple myeloma: a nationwide register-based study. Sci Rep (2026). https://doi.org/10.1038/s41598-026-59999-2 July 9, 2026.
Overview
This nationwide Danish study examined opioid use before a myeloma diagnosis and its relationship to survival. Opioid use began rising more than two years before diagnosis, and high prediagnostic use was independently associated with shorter overall survival, suggesting that escalating pain treatment may signal unrecognized disease.
"Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care"
Source
E. A. Martino, E. Vigna, A. Bruzzese, et al., “Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care,” European Journal of Haematology (2026): 1-17, https://doi.org/10.1111/ejh.70263. July 9, 2026.
Overview
This review examines the gap between efficacy in randomized myeloma trials and effectiveness in routine practice, where patients are often older and less fit. It advocates integrating clinical-trial and real-world evidence to improve individualized treatment decisions while accounting for selection, adherence, toxicity, and access.
"Therapy update: An introduction to the pharmacology, safety, and efficacy of bispecific antibodies in relapsed or refractory multiple myeloma"
Source
Dawud Ellayan, Therapy update: An introduction to the pharmacology, safety, and efficacy of bispecific antibodies in relapsed or refractory multiple myeloma, American Journal of Health-System Pharmacy, 2026;, zxag203, https://doi.org/10.1093/ajhp/zxag203 July 10, 2026.
Overview
This review summarizes the pharmacology, efficacy, and safety of approved and investigational bispecific antibodies for relapsed or refractory myeloma. It highlights strong single-agent activity alongside cytokine release syndrome, neurotoxicity, and infection risks that require step-up dosing, prophylaxis, and close monitoring.
"Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison."
Source
Richter, J., Lee, H. C., Jagannath, S., Zonder, J. A., Hoffman, J. E., Zhou, Z. Y., et al. Bumma, N. (2026). Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison. Leukemia & Lymphoma, 1-13. https://doi.org/10.1080/10428194.2026.2688561 July 10, 2026.
Overview
This matching-adjusted indirect comparison evaluated linvoseltamab versus elranatamab in triple-class-exposed relapsed or refractory myeloma. Linvoseltamab was associated with higher response rates and a restricted mean overall-survival advantage, although several time-to-event comparisons were not statistically significant.
"Comparative efficacy and safety of G-CSF alone versus G-CSF combined with different doses of cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma."
Source
Göçer M, Kurtoğlu E. Comparative efficacy and safety of G-CSF alone versus G-CSF combined with different doses of cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. Transfus Apher Sci. 2026 Jul 10;65(4):104490. doi: 10.1016/j.transci.2026.104490.
Overview
This retrospective study compared G-CSF alone with G-CSF plus low-or intermediate-dose cyclophosphamide for stem cell mobilization. Adding cyclophosphamide improved mobilization success and CD34-positive cell yield, with the higher dose producing the greatest efficacy without a significant increase in measured toxicity.
"Comprehensive Assessment of Flow Cytometry Light Chains: Qualitative and Quantitative Evaluation Using Serum Protein Immunofixation and Free Light Chain Analysis"
Source
A. Borai, M. Almowaled, A. Tayeb, et al., “Comprehensive Assessment of Flow Cytometry Light Chains: Qualitative and Quantitative Evaluation Using Serum Protein Immunofixation and Free Light Chain Analysis,” International Journal of Laboratory Hematology (2026): 1-9, https://doi.org/10.1111/ijlh.70180. July 10, 2026.
Overview
This laboratory study compared flow-cytometric light-chain testing with serum free light-chain assays and immunofixation in patients with and without monoclonal gammopathies. Flow cytometry showed high sensitivity and may complement established tests by identifying and quantifying clonal light-chain expression in bone marrow plasma cells.
"Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and Resistance."
Source
Mondal, S., Becker, N., Huo, Y., Zhang, P., Johnson, T. S., Landgren, C. O., Coffey, D. G., Walker, B. A., & Liu, E. (2026). Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and Resistance. Biomedicines, 14(7), 1556. https://doi.org/10.3390/biomedicines14071556 July 10, 2026.
Overview
This review explains how tumor-intrinsic changes and the bone marrow microenvironment drive resistance to CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. It emphasizes molecular profiling at relapse and rational sequencing or combination strategies, while noting that reuse of a previously targeted antigen may still be effective in selected patients.
"Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations with Neutropenia, Supportive Care Burden and Survival"
Source
Ahmet Yigitbasi, Fulya Oz Puyan, Hakki Onur Kirkizlar, Tugcan Alp Kirkizlar, Nuray Can, Ebru Tastekin, Seyma Keles Karahan, Elif Gulsum Umit, Ahmet Muzaffer Demir, Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations with Neutropenia, Supportive Care Burden and Survival, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.07.003. July 11, 2026.
Overview
This study evaluated clonal hematopoiesis as a host factor in newly diagnosed myeloma. Clonal hematopoiesis was associated with neutropenia, infections, transfusions, greater supportive-care needs, and inferior overall survival, suggesting value for risk assessment and care planning.
"Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma."
Source
Sra, M. S., & Kumar, S. (2026). Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2026.2703858 July 11, 2026.
Overview
This review summarizes resistance mechanisms across BCMA-directed CAR T cells, bispecific antibodies, and antibody-drug conjugates. It identifies antigen escape, T-cell dysfunction, and tumor-lineage plasticity as major barriers and discusses multi-antigen and combination approaches designed to overcome them.
"Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience."
Source
Close S, Liu J, Abousamra L, Konshina E, Shao C, Green E, et al. Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience. Transfusion. 2026. https://doi.org/10.1111/trf.70260 July 11, 2026
Overview
This real-world comparison evaluated motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization. Motixafortide was feasible but not superior and caused more injection-site and systemic reactions, leading the center to retain plerixafor as its default strategy.
"PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression."
Source
Iannozzi, N.T., Storti, P., Vescovini, R. et al. PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression. Cancer Gene Ther (2026). https://doi.org/10.1038/s41417-026- 01060-5 July 11, 2026.
Overview
This preclinical study investigated PYGO2 as a driver of aggressive myeloma with 1q21 amplification. PYGO2 promoted proliferation, cell-cycle progression, and proteasome-inhibitor resistance, while its suppression impaired tumor growth, identifying a potential therapeutic vulnerability.
"Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies."
Source
Solia E, Theodorakakou F, Malandrakis P, Ntanasis-Stathopoulos I, Kanellias N, Eleutherakis-Papaiakovou E, et al. Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies. Br J Haematol. 2026; 00: 1-8. https://doi.org/10.1111/bjh.70667 July 12, 2026.
Overview
This study characterized MGUS, smoldering myeloma, and asymptomatic Waldenstrom macroglobulinemia in patients younger than 50. Younger patients generally showed biology similar to that of older adults and low progression rates with protocol-based follow-up.
"The development of novel chimeric antigen receptor gamma-delta T cells against multiple myeloma and single-cell RNA sequencing analysis."
Source
Hong Y, Zhang C, Wang J, Zhang J, Zhu Y, Zhang Y, et al. The development of novel chimeric antigen receptor gamma-delta T cells against multiple myeloma and single-cell RNA sequencing analysis. Br J Haematol. 2026; 00: 1-12. https://doi.org/10.1111/bjh.70660 July 12, 2026.
Overview
This preclinical study developed BCMA-directed gamma-delta CAR T cells as a potential off-the-shelf therapy for myeloma. The cells killed myeloma effectively in vitro but persisted less well in vivo than conventional alpha-beta CAR T cells, identifying proliferation and persistence as priorities for further engineering.
"Differenzialdiagnosen maligner Knochenmarkerkrankungen [Differential diagnoses of malignant bone marrow diseases]."
Source
Reidler P, Friedrich D, Winkelmann M. Differenzialdiagnosen maligner Knochenmarkerkrankungen [Differential diagnoses of malignant bone marrow diseases]. Radiologie (Heidelb). 2026 Jul 13. German. doi: 10.1007/s00117-026-01645-z. Epub ahead of print.
Overview
This narrative review provides a practical radiologic approach to distinguishing malignant bone marrow disease from benign marrow conversion and other mimics. It emphasizes integrating MRI and CT patterns with fat content, mineralization, age, clinical history, and follow-up or biopsy when findings remain unclear.
"Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma."
Source
Pucci, M., Costanzo, E., Marfia, M., Seidita, G., Fontana, S., Corrado, C., & Alessandro, R. (2026). Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma. International Journal of Molecular Sciences, 27(14), 6276. https://doi.org/10.3390/ijms27146276 July 13, 2026.
Overview
This review examines extracellular vesicles as mediators of immune suppression, stromal remodeling, progression, and treatment resistance in myeloma. It also considers vesicles and their cargo as biomarkers and therapeutic targets within the bone marrow microenvironment.
"Exercise for myeloma patients with bone disease: a scoping review."
Source
Land, J., McCourt, O., Kyriakou, C. et al. Exercise for myeloma patients with bone disease: a scoping review. Support Care Cancer 34, 759 (2026). https://doi.org/10.1007/s00520-026-10958-7 July 13, 2026.
Overview
This scoping review assessed the safety, design, and outcomes of exercise interventions that included patients with myeloma bone disease. Exercise appeared feasible under selected conditions, but inconsistent adverse-event reporting and limited bone-specific outcomes prevent firm clinical guidance.
"Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype."
Source
Alana L. Keller, Kady A. Dennis, Denis J. Ohlstrom, Sarah E. Parzych, Zachary J. Walker, Amanda J. Novak, Catherine Pham-Danis, Tanisha N. Medha, Jeremy T. Rahkola, Meher P. Boorgula, M. Eric Kohler, Daniel W. Sherbenou; Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype. Cancer Immunol Res 2026; https://doi.org/10.1158/2326-6066.CIR-25-1068 July 13, 2026.
Overview
This laboratory study examined myeloma cells that survive CAR T-cell and T-cell-engager treatment. Persistent cells adopted a CD45-positive, checkpoint-rich immunoevasive phenotype, supporting research into combinations that pair T-cell redirection with checkpoint inhibition.
"Machine Learning for the Interpretation of Serum Protein and Immunofixation Electrophoresis in Multiple Myeloma: A Scoping Review."
Source
Mohd Murshid, N., Ahmad Azman, A. H., & Nasuruddin, D. N. (2026). Machine Learning for the Interpretation of Serum Protein and Immunofixation Electrophoresis in Multiple Myeloma: A Scoping Review. Diagnostics, 16(14), 2201. https://doi.org/10.3390/diagnostics16142201 July 13, 2026.
Overview
This scoping review mapped machine-learning methods for interpreting serum protein electrophoresis and immunofixation. Reported models approached expert accuracy, but limited external validation, single-center data, and poor explainability remain barriers to routine clinical use.
"Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma."
Source
Tan, C. R., Gordan, L., Richter, J., DiLeo, R., Mewawalla, P., Larson, S., et al. Usmani, S. (2026). Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future Oncology, 1-9. https://doi.org/10.1080/14796694.2026.2698699 July 14, 2026.
Overview
This real-world study compared frontline DVRd with VRd in transplant-eligible newly diagnosed myeloma, including subsequent maintenance. DVRd was associated with significantly longer progression-free survival, supporting the effectiveness of the quadruplet outside clinical trials.
"Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up."
Source
BSRI Study: Sæmundur Rögnvaldsson et al. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up. J Clin Oncol 0, JCO-25-02771 DOI:10.1200/JCO-25-02771 July 14, 2026.
Overview
This iStopMM study assessed clinical and psychological outcomes of population-based monoclonal gammopathy screening and randomized follow-up. Screening detected smoldering myeloma earlier and reduced symptomatic or hospitalized presentations without measurable psychological harm, although longer follow-up is needed to assess survival and cost-effectiveness.
"Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis."
Source
Kang, Y., Liu, Q., Liu, L. et al. Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01564-1 July 14, 2026.
Overview
This systematic review and meta-analysis compared salvage CAR T-cell therapy with engineered antibodies after prior BCMA-directed treatment. CAR T-cell therapy, particularly GPRC5D-directed CAR T cells, produced higher response rates, underscoring the importance of antigen selection and sequencing.
"Non-cryopreserved Hematopoietic Stem Cell Transplantation compared to Conventional Autologous Peripheral Stem Cell Transplantation with cryopreserved stem cells among patients newly diagnosed with Myeloma"
Source
Ece Vural, Ramazan Ocal, Hamit Aytekin, İlknur Aksoyoğlu, Oral Nevruz, Osman İlhan, Meral Beksac, Non-cryopreserved Hematopoietic Stem Cell Transplantation compared to Conventional Autologous Peripheral Stem Cell Transplantation with cryopreserved stem cells among patients newly diagnosed with Myeloma, Transfusion and Apheresis Science, 2026, 104493, ISSN 1473-0502, https://doi.org/10.1016/j.transci.2026.104493. July 14, 2026.
Overview
This study compared fresh, non-cryopreserved stem cells with conventional cryopreserved products for autologous transplantation. Fresh products produced slightly faster neutrophil recovery, fewer infusion reactions, and a one-day shorter hospital stay, although the clinical differences were modest.
"The synthetic landscape of cereblon (CRBN) binders: from thalidomide to emerging chemotypes."
Source
Sergi Rafael, Carolina Sánchez-Zarzalejo, Rory Whelan, Clifford Harris, Xavier Verdaguer, Cristina Mayor-Ruiz, Antoni Riera; The synthetic landscape of cereblon (CRBN) binders: from thalidomide to emerging chemotypes. Chem. Soc. Rev. 2026; https://doi.org/10.1039/d6cs00247a July 14, 2026.
Overview
This chemistry review traces cereblon binders from thalidomide and established IMiDs to newer molecular glues and degrader platforms. Its purpose is to connect binding chemistry with protein degradation and guide the design of more selective cereblon-directed therapies.
"A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects."
Source
Davanço, M. G., Vespasiano, T. P., Moisan, J., Gonzalez, O., Sarmiento, M., & Groleau, M. (2026). A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects. Pharmaceuticals, 19(7), 1089. https://doi.org/10.3390/ph19071089 July 14, 2026.
Overview
This crossover pharmacokinetic study compared a test pomalidomide capsule with the reference product in healthy Chilean adults. The formulations met regulatory bioequivalence criteria and were well tolerated.
"Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel."
Source
Kenneth J. C. Lim, Hee Eun Lee, Zongming Eric Chen, Adam Bledsoe, Ricardo Parrondo, Saurabh Chhabra, Katharine Dooley, Andre De Menezes Silva Corraes, Morie Gertz, Lisa Hwa, Haily Stephens, Prashant Kapoor, Melinda Tan, Taxiarchis Kourelis, Rahma Warsame, Joselle Cook, Moritz Binder, P. Leif Bergsagel, Udit Yadav, Erin Wiedmeier-Nutor, Susan Geyer, Sikander Ailawadhi, Rafael Fonseca, Shaji Kumar, Navreet Chowla, Yi Lin; Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel. Blood Adv 2026; 10 (13): 4495-4507. doi: https://doi.org/10.1182/bloodadvances.2025018853 July 14, 2026.
Overview
This Mayo Clinic series characterized immune effector cell-associated enterocolitis after cilta-cel and proposed diagnostic and management approaches. The uncommon syndrome presented as severe, persistent diarrhea with delayed onset and frequent coinfections, emphasizing prompt endoscopic evaluation and coordinated immunosuppressive and antimicrobial care.
"Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma."
Source
Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, Parker T, Green M, Thertulien R, Parsons B, Kumar P, Kapoor P, Rosenberg A, Dib E, Almquist D, Zonder J, Faber E, Wei Z, Anderson K, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar SV. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. N Engl J Med. 2026 Jul 16;395(3):221-232. doi: 10.1056/NEJMoa2600157.
Overview
This phase 3 trial compared continuous lenalidomide maintenance with a fixed two-year course in standard-risk patients who did not undergo upfront transplantation. Continuous therapy did not significantly improve overall survival and produced more adverse events, informing discussions about maintenance duration.
"Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy."
Source
Herzberg, F., Lu, F., Korenkov, M. et al. Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy. Leukemia (2026). https://doi.org/10.1038/s41375-026-03047-5 July 15, 2026.
Overview
This study developed an image-based ex vivo assay to predict response to teclistamab or talquetamab from patient bone marrow samples. Functional T-cell activation, expansion, and tumor-cell killing patterns identified distinct response phenotypes that may serve as biomarkers for selecting immunotherapy.
"The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma."
Source
Wan, X., Du, T., Fang, T. et al. The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01574-z July 15, 2026.
Overview
This preclinical study examined RAD23A, a protein linking DNA repair and proteasomal degradation, as a myeloma dependency. RAD23A depletion impaired repair, activated cellular stress and apoptosis, reduced tumor growth, and prolonged survival in models, supporting it as a therapeutic target.
"Validation and prognostic utility of the mSMART 4.0 risk stratification system in Chinese patients with multiple myeloma."
Source
Yin, J., Liu, R., Zhang, Y. et al. Validation and prognostic utility of the mSMART 4.0 risk stratification system in Chinese patients with multiple myeloma. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-16521-1 July 15, 2026.
Overview
This retrospective study validated the mSMART 4.0 risk system in a Chinese newly diagnosed myeloma cohort. The updated system more accurately predicted progression-free and overall survival than version 3.0 and independently identified patients with poor prognosis.
"Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry."
Source
Kylee H. Maclachlan, Marios Papadimitriou, Patrick Blaney, Linda B. Baughn, Tala Shekarkhand, Alexandra M. Poos, Bachisio Ziccheddu, Hongwei Tang, Huihuang Yan, Benjamin Diamond, Yanming Zhang, Robert Cimera, Ahmet Dogan, Dylan Gagler, Eileen Boyle, Malin Hultcrantz, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Carlyn Tan, Elizabeth E. Brown, Lara Winterkorn, Timothy Chu, Zoe Steinsnyder, Zalman Vaksman, Faith E. Davies, Neha Korde, Ola Landgren, Marc S. Raab, Alexander M. Lesokhin, Nicolas Robine, Niels Weinhold, Saad Z. Usmani, Francesco Maura, Gareth J. Morgan; Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry. Blood Cancer Discov 2026; https://doi.org/10.1158/2643-3230.BCD-25-0259 July 16, 2026
Overview
This genomic analysis asked whether inherited or tumor genomic differences explain ancestry-related disparities in myeloma risk. Most genomic drivers occurred at similar rates across African-and European-ancestry groups, and outcomes were comparable with equal treatment access, pointing to non-genomic contributors to disparities.
"Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients."
Source
Albrecht, N., Boeckx, E., Caers, J. et al. Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients. Ann Hematol (2026). https://doi.org/10.1007/s00277-026-07110-0 July 16, 2026
Overview
This expert consensus provides multidisciplinary recommendations for managing talquetamab-related oral, skin, nail, and nutritional adverse events. Early education, oral and dermatologic care, dose modification, and dietitian involvement are emphasized to preserve quality of life and treatment adherence.
"Association of the triglyceride-glucose index with tumor burden in newly diagnosed multiple myeloma: A retrospective cross-sectional study"
Source
Jing Zhang, Dan Xu, Ran Luo, Wentao Shu, Dongfeng Zeng, Xiaona Bu, Association of the triglyceride-glucose index with tumor burden in newly diagnosed multiple myeloma: A retrospective cross-sectional study, Clinica Chimica Acta, 2026, 121234, ISSN 0009-8981, https://doi.org/10.1016/j.cca.2026.121234. July 16, 2026.
Overview
This retrospective study examined the triglyceride-glucose index as an accessible marker of disease burden in newly diagnosed myeloma. A higher index was strongly associated with greater marrow plasma-cell infiltration, warranting prospective validation as a metabolic biomarker.
"Predictors of survival and functional outcomes after spinal surgery for multiple myeloma: a nationwide study of 200 patients."
Source
Albarni, A., Parai, C., Carrwik, C. et al. Predictors of survival and functional outcomes after spinal surgery for multiple myeloma: a nationwide study of 200 patients. Eur Spine J (2026). https://doi.org/10.1007/s00586-026-10196-9 July 16, 2026
Overview
This nationwide study identified factors associated with survival and function after spinal surgery for myeloma. Advanced stage, older age, inability to walk before surgery, and later spinal involvement predicted poorer survival, while many selected patients regained or maintained mobility and experienced less pain.
"Ultra-High-Resolution Dual-Source Photon-Counting CT for Expanded Characterization of Pathophysiological Imaging Patterns in Multiple Myeloma."
Source
Bley, T. A., Kortuem, K. M., Heidemeier, A., Einsele, H., Waldschmidt, J. M., Huflage, H., Grunz, J.-P., & Rasche, L. (2026). Ultra-High-Resolution Dual-Source Photon-Counting CT for Expanded Characterization of Pathophysiological Imaging Patterns in Multiple Myeloma. Investigative Radiology https://doi.org/10.1097/RLI.0000000000001304 July 16, 2026.
Overview
This imaging study evaluated ultra-high-resolution dual-source photon-counting CT for marrow and skeletal patterns in myeloma. It identified a fat-attenuation-predominant phenotype not captured by current focal-lesion definitions, suggesting that spectral and morphologic features may complement standard criteria.
"Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma."
Source
Goel, U., Dragomirescu, C., Chedid, R. et al. Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma. Blood Cancer J. 16, 116 (2026). https://doi.org/10.1038/s41408-026-01582-z July 16, 2026.
Overview
This Letter to the Editor evaluated how early depth and speed of response after ide-cel relate to later outcomes in relapsed or refractory myeloma. The analysis highlights post-infusion response kinetics as prognostic information that may complement pre-infusion risk factors and help identify patients needing closer monitoring or earlier intervention.
"Risk factors and their contributions to prognosis in multiple myeloma."
Source
Chung T-H, Chang JG, Tan TK, Chng WJ. Risk factors and their contributions to prognosis in multiple myeloma. Haematologica; https://doi.org/10.3324/haematol.2025.300217 [Early view]. July 16, 2026.
Overview
This CoMMpass analysis evaluated conventional high-risk lesions alongside APOBEC activity, chromothripsis, gene-expression, and proliferation markers. Combining diverse risk factors improved survival prediction and demonstrated a strong multi-hit effect, supporting broader genomic risk assessment beyond current recommendations.
"Protein Profile of Multiple Myeloma-Derived Extracellular Vesicles for the Discovery of Novel Myeloma-Related Biomarkers"
Source
N. Platonova, G. Aiello, D. Ronchetti, et al., “Protein Profile of Multiple Myeloma-Derived Extracellular Vesicles for the Discovery of Novel Myeloma-Related Biomarkers,” Cancer Science (2026): 1-14, https://doi.org/10.1111/cas.70473. July 16, 2026.
Overview
This proteomic study evaluated myeloma-derived extracellular vesicles as a source of noninvasive biomarkers. It identified MIF and prohibitin as candidates and found elevated, partly vesicle-associated MIF in smoldering and active myeloma, supporting further validation for early detection and monitoring.
"Establishment of a Multimodal Prognostic Prediction Model for Multiple Myeloma Patients Based on Radiomics and Clinical Features: A Retrospective Cohort Study."
Source
Sun S, Huang Z, Tang Y, Gu W, Wu L, Shen F. Establishment of a Multimodal Prognostic Prediction Model for Multiple Myeloma Patients Based on Radiomics and Clinical Features: A Retrospective Cohort Study. Turk J Haematol. 2026 Jul 16. doi: 10.4274/tjh.galenos.2026.33678. Epub ahead of print.
Overview
This retrospective study developed machine-learning survival models that combine radiomics with clinical features in newly diagnosed myeloma. The integrated model improved early progression-free-survival prediction and identified imaging risk score, beta-2 microglobulin, age, LDH, calcium, platelets, and hemoglobin as important contributors.
"Study of post-translational modifications of p53 in multiple myeloma."
Source
Rojas, E.A., Cristóbal-Vargas, S., Becerro-Recio, D. et al. Study of post-translational modifications of p53 in multiple myeloma. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01568-x July 17, 2026.
Overview
This study investigated non-genetic regulation of p53 through phosphorylation and acetylation in primary myeloma samples. The work documents substantial variation in p53 post-translational states and explores their relationship to DNA-damage signaling, disease biology, and prognosis.
"Temporal trends and demographic patterns in multiple myeloma incidence in the United States: a 24-year analysis of the CDC WONDER database (1999-2022)."
Source
Mahajan, S., Oberoi, V.S., Massat, B. et al. Temporal trends and demographic patterns in multiple myeloma incidence in the United States: a 24-year analysis of the CDC WONDER database (1999-2022). Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01577-w July 17, 2026.
Overview
This CDC WONDER analysis described 24 years of U.S. myeloma incidence trends. Incidence rose over time and remained disproportionately high among men, older adults, Black individuals, and non-Hispanic populations, reinforcing the need to investigate demographic disparities.
"Detailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies."
Source
Pérez-Escurza, O., Kolijn, P.M., Óskarsson, J.Þ. et al. Detailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01579-8 July 18, 2026.
Overview
This study used next-generation flow cytometry and sequencing to characterize clonal plasma cells and B cells in early monoclonal gammopathies. Distinct WM-like and myeloma-like patterns improved biologic classification beyond conventional criteria and may help clarify early disease pathways.
"Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US"
Source
Brandon J. Blue, Andrew K. ElHabr, Benjamin A. Derman, Avik Ray, Jie Ting, Ken Hasegawa, Zizi Elsisi, Kian Farajkhah, Turgay Ayer, Attaya Suvannasankha, Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.07.009. July 18, 2026.
Overview
This national claims analysis examined geographic and socioeconomic barriers to myeloma CAR T-cell therapy. Longer travel distance, nonmetropolitan residence, and lower household income independently reduced use, supporting targeted expansion of authorized treatment centers and access programs.
"In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma"
Source
G. Vardhan, V. Kumar, A. Kumar, S. Handu, and P. Dhamija, “In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma,” Chirality 38, no. 8 (2026): e70125, https://doi.org/10.1002/chir.70125. July 18, 2026.
Overview
This computational docking study compared how pomalidomide enantiomers bind several immunomodulatory targets. The S-enantiomer showed stronger predicted binding to cereblon and TNF-alpha-related targets, but the findings require experimental and clinical validation.
"Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma."
Source
Kumar, S., Knopf, B., Asmus, E. et al. Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01567-y July 18, 2026.
Overview
This trial evaluated fixed-duration daratumumab, ixazomib, lenalidomide, and dexamethasone for newly diagnosed myeloma and tested early steroid discontinuation. The regimen produced high response rates and increasing MRD negativity, while stopping dexamethasone early did not appear to reduce efficacy.
"Fractional modeling of CD38-mediated multiple myeloma dynamics with immune interaction and therapy effects dynamics."
Source
Khirsariya, S.R., Thakker, C. & Noori, N. Fractional modeling of CD38-mediated multiple myeloma dynamics with immune interaction and therapy effects dynamics. Sci Rep (2026). https://doi.org/10.1038/s41598-026-61683-4 July 19, 2026.
Overview
This study developed a fractional-order mathematical model of CD38-positive myeloma, immune interactions, and therapy effects. Simulations illustrate how immune clearance, tumor growth, treatment, and biologic memory may shape disease control and resistance.
"Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma."
Source
Sumankan, R., Sungwan, P., Boonsatit, N. et al. Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma. Cancer Immunol Immunother (2026). https://doi.org/10.1007/s00262-026-04431-x July 20, 2026.
Overview
This preclinical study tested a CD47-directed trispecific NK-cell engager containing IL-15. The agent enhanced NK-cell expansion, cytotoxicity, and macrophage phagocytosis and suppressed myeloma growth in mouse models, supporting further therapeutic development.
"Frontline T cell-redirecting therapies in newly diagnosed multiple myeloma: key signals from the 2025 ASH Annual Meeting."
Source
Zhou, H., Jin, X., Chen, W. et al. Frontline T cell-redirecting therapies in newly diagnosed multiple myeloma: key signals from the 2025 ASH Annual Meeting. Exp Hematol Oncol 15, 63 (2026). https://doi.org/10.1186/s40164-026-00809-w July 20, 2026.
Overview
This review summarizes early frontline data on CAR T cells and bispecific antibodies presented at the 2025 ASH meeting. Deep responses and MRD negativity were encouraging, but short follow-up, heterogeneous assays, and infection risk support randomized trials of fixed-duration or response-adapted strategies.
"Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool."
Source
Usmani, Jonathan U. Peled, Urvi A. Shah, Alexander M. Lesokhin; Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool. Clin Cancer Res 2026; https://doi.org/10.1158/1078-0432.CCR-26-0752 July 20, 2026.
Overview
This prospective study examined the microbiome and bile-acid pool in lenalidomide-related diarrhea. The findings implicate impaired microbial bile-acid metabolism and support testing microbiota-directed approaches to prevent or treat this chronic toxicity.
"Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study."
Source
Cottrell, J. L., Casillas, A., Nnawuba, K. C., Tidd, S. J., Robinson, S. E., Rahman, M. M., et al. Jensen, H. (2026). Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study. Cancer Investigation, 1-7. https://doi.org/10.1080/07357907.2026.2703020 July 20, 2026.
Overview
This single-center retrospective study compared survival among Black and White patients treated at a dedicated myeloma center. Outcomes did not differ significantly by race, suggesting that centralized expertise and more equitable access may mitigate disparities.
"Immunomagnetic nanoprobe-mediated capture of circulating multiple myeloma cells for monitoring of proteasome inhibitor response."
Source
Lai R, Li M, Zhang H, Zou S, Yan Y, Wu S, Qiao Y, Cheng X, Wang T, Li C. Immunomagnetic nanoprobe-mediated capture of circulating multiple myeloma cells for monitoring of proteasome inhibitor response. IEEE Trans Nanobioscience. 2026 Jul 20;PP. doi: 10.1109/TNB.2026.3715269. Epub ahead of print.
Overview
This study developed an immunomagnetic nanoprobe to capture circulating myeloma cells from blood and monitor proteasome-inhibitor response. Cell counts tracked disease stage and rose with progression while falling with favorable response, supporting minimally invasive treatment monitoring.
"Targeting the mevalonate pathway sensitizes multiple myeloma cells to bortezomib through induction of mitochondrial metabolic disruption."
Source
Li, S., Hu, N., Li, X. et al. Targeting the mevalonate pathway sensitizes multiple myeloma cells to bortezomib through induction of mitochondrial metabolic disruption. Cell Commun Signal (2026). https://doi.org/10.1186/s12964-026-03076-8 July 20, 2026.
Overview
This preclinical study investigated the mevalonate pathway as a mediator of bortezomib resistance. Pathway inhibition, including with statins, disrupted mitochondrial metabolism and sensitized myeloma cells to bortezomib, supporting further study of the combination.
"Response-adapted lenalidomide-dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study."
Source
Minakata, D., Yamamoto, G., Kako, S. et al. Response-adapted lenalidomide-dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study. Blood Res. 61, 37 (2026). https://doi.org/10.1007/s44313-026-00154-1 July 20, 2026.
Overview
The PIANO study tested lenalidomide-dexamethasone intensification after inadequate response to CyBorD before autologous transplantation. Intensification improved pretransplant responses in some patients but did not improve the primary post-transplant complete-response endpoint versus historical results.
"SECURE study: baseline findings from a UK prospective cohort of incidentally detected MGUS."
Source
Knight, E., Krishnamoorthi, A., Balik, B. et al. SECURE study: baseline findings from a UK prospective cohort of incidentally detected MGUS. Blood Cancer J. 16, 119 (2026). https://doi.org/10.1038/s41408-026-01576-x July 20, 2026.
Overview
This Letter to the Editor reports baseline findings from the prospective UK SECURE cohort of incidentally detected MGUS. It characterizes diagnostic pathways, monitoring, patient-reported effects, and unmet needs to strengthen evidence for risk communication and follow-up in routine care.
"Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation."
Source
Ravi G, Dhakal B, Callander NS, et al. Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation. Cancer. 2026;e70478. doi:10.1002/cncr.70478 July 20, 2026.
Overview
This study reassessed functional high-risk myeloma in patients receiving frontline quadruplet therapy and autologous transplantation. Progression within 36 months best defined the contemporary high-risk group, while T-cell-redirecting therapy improved outcomes after progression.
"Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma."
Source
Mariotti, E.G., Kumar, S., Gonsalves, W. et al. Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma. Leukemia (2026). https://doi.org/10.1038/s41375-026-03075-1 July 21, 2026.
Overview
This study examined whether high-risk cytogenetics retain prognostic value among patients who are MRD-negative after autologous transplantation. Several abnormalities, including isolated del(17p), 1q21 gain, t(4;14), and MAF translocations, remained associated with inferior progression-free survival despite MRD negativity.
"Risk factors and clinical impact of bone pain in patients with multiple myeloma - A prospective interdisciplinary study"
Source
Carlotta Pietsch, Monika Engelhardt, Julian P. Maier, Gabriele Ihorst, Hagen Schmal, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Ralph Wäsch, Georg W. Herget, Risk factors and clinical impact of bone pain in patients with multiple myeloma - A prospective interdisciplinary study, Journal of Bone Oncology,2026, 100788, ISSN 2212-1374, https://doi.org/10.1016/j.jbo.2026.100788. July 21, 2026.
Overview
This prospective interdisciplinary study identified predictors and consequences of bone pain in myeloma. Osteolytic lesions at fracture risk and pre-existing orthopedic disease independently predicted pain, which was associated with worse quality of life and supports coordinated oncologic and orthopedic care.
"Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study."
Source
Yan Q, Chu B, Liu M, Ji N, Gao S, Lu M, Shi L, Fang L, Xiang Q, Chen Y, Wang M, Bao L. Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study. Clin Transl Sci. 2026 Jul;19(7):e70660. doi: 10.1111/cts.70660.
Overview
This longitudinal study measured circulating myeloid-derived suppressor cells during induction and after transplantation. VRd caused a temporary rise in monocytic suppressor cells associated with shallower response, but the change was not independently predictive after adjustment.
"American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis."
Source
Vishal Kukreti, Matthew Seftel, Maria Adela Aguirre, Muayad Azzam, Deborah D. Boedicker, Naresh Bumma, Antonia S. Carroll, Raymond Comenzo, Joselle Cook, Noel Dasgupta, Alfredo De La Torre, Angela Dispenzieri, Faizi Jamal, Hassan Kawtharany, Jack Khouri, Nelson Leung, Jamil Nazzal, Maria M. Picken, Shahzad Raza, Vaishali Sanchorawala, Nitasha Sarswat, Hira Shaikh, Daulath Singh, Reem A. Mustafa; American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis. Blood Adv 2026; 10 (14): 5113-5152. doi: https://doi.org/10.1182/bloodadvances.2025017073 July 28, 2026.
Overview
These ASH guidelines provide evidence-based recommendations for the timely diagnosis of light-chain amyloidosis across cardiac, renal, neurologic, and other presentations. They address testing strategies, tissue biopsy, amyloid typing, and important evidence gaps to support consistent multidisciplinary diagnosis.
"Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy."
Source
Doris K. Hansen, Maria Victoria Mateos, Luciano J. Costa; Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy. Blood Adv 2026; 10 (14): 4931-4940. doi: https://doi.org/10.1182/bloodadvances.2026019699 July 28, 2026.
Overview
This review synthesizes phase 3 evidence for BCMA-directed CAR T cells, bispecific antibodies, and antibody-drug conjugates after one to three prior lines of therapy. It emphasizes individualized selection based on fitness, prior exposure, toxicity, logistics, access, and patient preferences.
"Cytomegalovirus reactivation in patients with multiple myeloma receiving bispecific antibodies."
Source
Enric Sastre-Escolà, Gemma K. Reynolds, Michelle K. Yong, Violet Zhu, Simon J. Harrison, Amit S. Khot, Monica A. Slavin, Benjamin W. Teh; Cytomegalovirus reactivation in patients with multiple myeloma receiving bispecific antibodies. Blood Adv 2026; 10 (14): 4907-4911. doi: https://doi.org/10.1182/bloodadvances.2025019563 July 28, 2026.
Overview
This Letter to the Editor describes cytomegalovirus reactivation in patients receiving bispecific antibodies for myeloma. It characterizes timing, clinical consequences, and risk factors and highlights the need for heightened surveillance and clearer prevention and treatment strategies in this immunocompromised population.
"Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications"
Source
María Carretero-Fernández, Antonio José Cabrera-Serrano, Lucía Ruíz Durán, Mariam Ibañez, Marco Bonilla, Francisco Mesa, Juan Francisco Gutiérrez-Bautista, Rachid Chahboun, Fernando Jesús Reyes-Zurita, Joaquín Martínez-Lopez, Rosa Collado, Juan Sainz, Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications, Translational Oncology, Volume 69, 2026, 102796, ISSN 1936-5233, https://doi.org/10.1016/j.tranon.2026.102796. July 2026.
Overview
This review presents myeloma as an evolving genomic ecosystem shaped by germline susceptibility, founding cytogenetic events, clonal evolution, and treatment pressure. It explains how integrated germline and somatic profiling may improve risk assessment and monitoring while noting that polygenic risk scores remain investigational.
"Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review"
Source
Mohyuddin G, Vaquera-Alfaro H, Godara A et al. Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review eClinicalMedicine, 2026; 97 July 2026.
Overview
This systematic review examined why identical VRd or Rd regimens produced different progression-free-survival results across trials conducted at different times. Changing diagnostic criteria, patient populations, and censoring patterns contributed to temporal drift, cautioning against informal cross-trial comparisons.
"Whole-body reduced-dose dual-energy CT with deep learning image reconstruction for detection of osteolytic lesions in multiple myeloma"
Source
Y. Li, Y. Cheng, Y. Ye, R. He, X. Tang, C. Hang, R. Zhao, Y. Yu, L. Wang, X. Li, Whole-body reduced-dose dual-energy CT with deep learning image reconstruction for detection of osteolytic lesions in multiple myeloma, Radiography, Volume 32, Issue 5, 2026, 103450, ISSN 1078-8174, https://doi.org/10.1016/j.radi.2026.103450. July 2026.
Overview
This prospective imaging study compared reduced-dose dual-energy CT with deep-learning reconstruction against routine-dose single-energy CT. The reduced-dose method improved image quality and osteolytic-lesion detection while lowering radiation exposure by 53%.
"Single-nucleotide variants as potential prognostic biomarkers in newly diagnosed multiple myeloma patients"
Source
David Garrido, Martín Ledesma, Flavia Stella, Camila Galvano, Sergio Lopresti, Eloísa Riva, Ariela Fundia, Irma Slavutsky, Single-nucleotide variants as potential prognostic biomarkers in newly diagnosed multiple myeloma patients, Hematology, Transfusion and Cell Therapy, Volume 48, Issue 3, 2026, 106464, ISSN 2531-1379, https://doi.org/10.1016/j.htct.2026.106464. July-September 2026.
Overview
This study used microarrays to identify single-nucleotide variants with prognostic value in newly diagnosed myeloma and to distinguish myeloma from MGUS. Variants in PTPRD, NOTCH4, SH3RF3, DCC, and CSMD1 emerged as candidates for risk stratification but require validation and functional study.